Table 1 Patient and disease characteristics
Characteristics | Total (n = 106) | ICI (n = 51) | Non-ICI (n = 55) | p† | |||
|---|---|---|---|---|---|---|---|
Median age (median, [range]) | 64 (38–82) | 62 (36–76) | 66 (38–82) | 0.004 | |||
Sex (n [%]) | 0.051 | ||||||
Male | 89 (84.0) | 40 (78.4) | 49 (89.1) | ||||
Female | 17 (16.0) | 11 (21.6) | 6 (10.9) | ||||
ECOG PS before CCRT (n [%]) | 0.570 | ||||||
0–1 | 97 (91.5) | 45 (88.2) | 52 (94.5) | ||||
2 | 7 (6.6) | 5 (9.8) | 2 (3.6) | ||||
3 | 2 (1.9) | 1 (2.0) | 1 (1.8) | ||||
ECOG PS before ICI (n [%]) | |||||||
0–1 | 45 (88.2) | ||||||
2 | 3 (5.9) | ||||||
Unavailable | 3 (5.9) | ||||||
Underlying lung disease (n [%]) | 21 (19.8) | 9 (17.6) | 12 (21.8) | 0.087 | |||
ILD | 1 (0.9) | 1 (2.0) | 0 (0.0) | ||||
COPD | 13 (12.3) | 4 (7.8) | 9 (16.4) | ||||
Asthma | 4 (3.8) | 0 (0.0) | 4 (7.3) | ||||
TB | 8 (7.5) | 4 (7.8) | 4 (7.3) | ||||
Smoking status (n [%]) | 0.255 | ||||||
(Ex-) smoker | 82 (77.4) | 37 (72.5) | 45 (81.8) | ||||
Never-smoker | 24 (22.6) | 14 (27.5) | 10 (18.2) | ||||
PFT (mean, [range]) | |||||||
FVC, % | 83.0 (54.0–118.0) | 85.0 (57.0–118.0) | 82.0 (54.0–110.0) | 0.202 | |||
FEV1, L | 2.00 (0.89–3.61) | 3.00 (0.89–3.57) | 2.00 (1.05–3.61) | 0.076 | |||
FEV1, % | 76.0 (24.0–118.0) | 78.0 (24.0–118.0) | 74.0 (33.0–114.0) | 0.221 | |||
DLCO, % | 75.0 (36.0–124.0) | 81.0 (48.0–132.0) | 71.0 (36.0–124.0) | 0.013 | |||
Tumor histology (n [%]) | 0.710 | ||||||
SqCC | 52 (49.1) | 22 (43.1) | 30 (54.5) | ||||
Adenocarcinoma | 50 (47.2) | 29 (56.9) | 21 (38.2) | ||||
Others | 4 (3.8) | 0 (0.0) | 4 (7.3) | ||||
Tumor location (n [%]) | |||||||
Right upper lobe | 43 (40.6) | 26 (51.0) | 17 (30.9) | 0.018 | |||
Right middle lobe | 4 (3.8) | 3 (5.9) | 1 (1.8) | ||||
Right lower lobe | 15 (14.2) | 5 (9.8) | 10 (18.2) | ||||
Left upper lobe | 32 (30.2) | 14 (27.5) | 18 (32.7) | ||||
Left lower lobe | 12 (11.3) | 3 (5.9) | 9 (16.4) | ||||
Stage (n [%]) | 0.657 | ||||||
IIA | 10 (9.4) | 5 (9.8) | 5 (9.1) | ||||
IIIA | 27 (25.5) | 10 (19.6) | 17 (30.9) | ||||
IIIB | 53 (50.0) | 29 (56.9) | 24 (43.6) | ||||
IIIC | 16 (15.1) | 7 (13.7) | 9 (16.4) | ||||
EGFR mutation (n [%]) | |||||||
Positive | 11 (10.4) | 5 (9.8) | 6 (10.9) | 0.334 | |||
Negative | 36 (34.0) | 20 (39.2) | 16 (29.1) | ||||
Not checkable | 59 (55.7) | 26 (51.0) | 33 (60.0) | ||||
PD-L1 test (n [%]) | |||||||
Positive | 36 (70.6) | ||||||
Negative | 8 (15.7) | ||||||
Not checkable | 7 (13.7) | ||||||
Chemotherapy agent during CCRT (n [%]) | |||||||
Paclitaxel/ Cisplatin | 71 (67.0) | 42 (82.4) | 29 (52.7) | 0.022 | |||
Paclitaxel/ Carboplatin | 15 (14.2) | 3 (5.9) | 12 (21.8) | ||||
Etoposide/ Cisplatin | 14 (13.2) | 4 (7.8) | 10 (18.2) | ||||
Etoposide/ Carboplatin | 5 (4.7) | 2 (3.9) | 3 (5.5) | ||||
Cisplatin/ Pemetrexed | 1 (0.9) | 0 (0.0) | 1 (1.8) | ||||
No. of cycles of chemotherapy (median, [range]) | 6 (2–8) | 6 (2–7) | 6 (2–8) | 0.233 | |||
Dosimetric parameters | |||||||
Total dose (median, [range]) | 66.0 (46.0–73.0) | 66.0 (46.0–69.0) | 66.0 (54.0–73.0) | 0.441 | |||
PTV size, cm3 (median, [range]) | 317.6 (104.8–1250.6) | 329.9 (136.8–1250.6) | 296.6 (104.8–847.2) | 0.216 | |||
MLD, Gy (median, [range]) | 13.1 (2.7–21.6) | 13.3 (2.7–21.3) | 12.1 (3.9–21.6) | 0.919 | |||
V5, %, (median, [range]) | 45.8 (7.5–83.5) | 46.8 (7.5–83.4) | 45.3 (12.7–83.5) | 0.557 | |||
V10, %, (median, [range]) | 33.2 (5.8–61.4) | 33.2 (5.8–59.9) | 32.8 (9.5–61.4) | 0.611 | |||
V20, %, (median, [range]) | 22.3 (3.2–45.5) | 22.6 (3.2–45.5) | 20.9 (7.1–41.4) | 0.982 | |||
V30, %, (median, [range]) | 16.3 (1.1–36.5) | 17.5 (1.1–29.3) | 15.8 (3.6–36.5) | 0.705 | |||
V40, % (median, [range]) | 12.3 (0.3–25.1) | 13.2 (0.3–25.1) | 11.2 (2.0–24.0) | 0.399 | |||